News

Sabine Tejpar, MD, PhD, University Hospitals Leuven

Videos

Single Cell Analysis and Transcriptomics in Colorectal Cancer

08/24/2023

Featuring Sabine Tejpar, MD, PhD

Featuring Sabine Tejpar, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Sabine Tejpar, MD, PhD, explained the application of single cell analyses in colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Guillem Argiles, MD, Memorial Sloan Kettering Cancer Center

Videos

Mechanisms of Response to Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer

08/24/2023

Featuring Guillen Argiles, MD

At the 2023 World Congress on Gastrointestinal Cancers, Guillen Argiles, MD, discussed the mechanisms of response to immune checkpoint inhibitors in colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Erika Martinelli, MD, PhD, Università degli Studi della Campania “L. Vanvitelli”

Videos

Upcoming Advancements in the Treatment of BRAF-Mutant, Metastatic Colorectal Cancer

08/23/2023

Featuring Erika Martinelli, MD, PhD

Featuring Erika Martinelli, MD, PhD ...

At the 2023 World Congress on Gastrointestinal Cancers, Erika Martinelli, MD, PhD, highlighted key upcoming advancements for the treatment of BRAF-mutant metastatic colorectal cancer.

At the 2023 World Congress on...

08/23/2023

Oncology

Alberto Sobrero, MD, Ospedale San Martino

Videos

Groundbreaking Advancements in Colorectal Cancer From the Past 25 Years

08/23/2023

Featuring Alberto Sobrero, MD

At the 2023 World Congress on Gastrointestinal Cancers, Alberto Sobrero, MD, highlighted key advancements in colorectal cancer from the past 25 years.

At the 2023 World Congress on...

08/23/2023

Oncology

Alfonso De Stefano, MD, PhD, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Giovanni Pascale

Videos

Intermittent vs Continuous Panitumumab Plus FOLFIRI for First-Line Treatment of Patients With RAS/BRAF Wild-Type Colorectal Cancer

08/21/2023

Featuring Alfonso De Stefano, MD, PhD

Featuring Alfonso De Stefano, MD, PhD...

At the 2023 World Congress on Gastrointestinal Cancers, Alfonso De Stefano, MD, PhD presented results of the IMPROVE study on intermittent or continuous panitumumab plus FOLFIRI for the first-line treatment of patients with RAS/BRAF wild-type...

At the 2023 World Congress on...

08/21/2023

Oncology

Eric Lander, MD, Vanderbilt University Medical Center

Videos

Tumor Mutational Signatures Among Patients With Early-Onset Versus Average-Onset Colorectal Cancer

08/21/2023

Featuring Eric Lander, MD

At the 2023 World Congress on Gastrointestinal Cancers, Eric Lander, MD, presents genomic clustering data suggesting that early-onset colorectal cancer may be caused by unique mutagenic processes compared to average-onset colorectal cancer.

At the 2023 World Congress on...

08/21/2023

Oncology

Muhammad Danyal Ahsan, New York Presbyterian Hospital, Weill Cornell Medicine

Videos

Mutational Landscape of Homologous Recombination Deficiency Pathogenic Gene Variants in Colorectal Cancer

08/18/2023

Featuring Muhammad Danyal Ahsan

Featuring Muhammad Danyal Ahsan ...

At the 2023 World Congress on Gastrointestinal Cancers, Muhammad Danyal Ahsan discusses results from a study that utilized the GENIE database to determine the potential utility of widespread functional HRD status assessment in colorectal...

At the 2023 World Congress on...

08/18/2023

Oncology

Gerald Prager, MD, Medical University of Vienna

Videos

Trifluridine/Tipiracil Plus Bevacizumab For Refractory Metastatic Colorectal Cancer

08/11/2023

Featuring Gerald Prager, MD

At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.

At the 2023 World Congress on...

08/11/2023

Oncology

News

Effect of HER2 Overexpression or Amplification on Resistance to Anti-EGFR Treatment Among Patients with RAS Wild-Type Metastatic Colorectal Cancer

08/10/2023

Allison Casey

According to a systemic review and meta-analysis, patients with HER2-positive, RAS wild-type metastatic colorectal cancer who were treated with anti-EGFR therapies were more likely to have worse progression-free survival and response than...

According to a systemic review...

08/10/2023

Oncology

News

Second-Line Avelumab Improved PFS and Disease Control Among Patients With dMMR/MSI Metastatic Colorectal Cancer

08/10/2023

Allison Casey

According to a phase 2 trial, avelumab had better efficacy and tolerability among patients with deficient mismatch repair and/or microsatellite instability metastatic colorectal cancer compared with standard-of-care chemotherapy.

According to a phase 2 trial,...

08/10/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology